EC Clinical and Medical Case Reports

Background: Amyloidosis is one of rare diseases is usually fatal. Increasingly recognized in clinical practice despite patients presenting with non-specific symptoms of cardiomyopathy for cardiac amyloidosis. Amyloidosis is a systemic illness that affects multiple organ systems, including the cardiovascular, renal, gastrointestinal, and pulmonary systems. Common manifestations include restrictive cardiomyopathy, arrhythmias, nephrotic syndrome, and gastrointestinal hemorrhage.

It is unknown whether coexisting atrial fibrillation (AF). Due to amyloidosis is considered as a rare disease according to The European Union considers a disease as rare when it affects less than 1 in 2,000 citizens. With characterization of wide diversity of symptoms and signs that vary not only from disease to disease but also from patient to patient suffering from the same disease. With all the previous features many question was raised from policy prospective like the nature of health system for disease management, system capacity and capability decision makers awareness about disease nature. Resources needed and accepility challenges. The objective for this research is policy analysis for the following items (nature of health system for disease management, system capacity and capability decision makers awareness about disease nature. Resources needed and accepility challenges).

In order to health system enhancement towards amyloidosis management for achievement better patients outcomes and efficient resources management.

Methods: Standardized survey was developed and conducted for 100 of HCPs (healthcare professionals) at the following countries (Algeria, Morocco, Egypt, KSA, UAE Iraq, Oman and Turkey) HCPs included (Physicians, nurses, pharmacists and payers).

Patient’s groups are represented at the survey. Previous survey with integrated with health systems data bases and nationals health accounts analysis for these countries for previous 5 years. One way sensitivity analysis was conducted for robustness of data guaranteeing.

Results: Analysis for amyloidosis founded the following findings:

• A systemic illness that affects multiple organ systems.
• Usually fatal for cardiac amyloidosis.
• Without efficient policy it might represent burden on health system.
• Stake holders engagement represent the corner stone for system enhancement.
• Accepility challenges presented at diseases management policies.
• Clear treatment guidelines combined with effective awareness and specialized clinics might have positive impact on policy enhancement.

Conclusion: Amyloidosis management at MENA region need policy reforming in order to achieve the following:

• Patient’s outcomes enhancement.
• Efficient resources utilization.
• Health system enhancement.

Keywords: Amyloidosis Accepility; MENA; Abdalla Abotaleb Policy; Analysis

1. Griffin JM., et al. “Pathophysiology and therapeutic approaches to cardiac amyloidosis”. Circulation Research 128 (2021): 1554-1575.
2. Nativi-Nicolau J and Maurer MS. “Amyloidosis cardiomyopathy: Update in the diagnosis and treatment of the most common types”. Current Opinion in Cardiology 33 (2018): 571-579.
3. Macedo AVS., et al. “Advances in the treatment of cardiac amyloidosis”. Current Treatment Options in Oncology 21 (2020): 36.
4. Knight DS., et al. “Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles”. JACC: Cardiovascular Imaging 12 (2019): 823-833.
5. Wechalekar AD., et al. “Systemic amyloidosis”. Lancet10038 (2016): 2641-2654.
6. Lachmann HJ and Hawkins PN. “Systemic amyloidosis”. Current Opinion in Pharmacology2 (2006): 214-220.
7. Gillmore JD., et al. “Cumulative SAA production and outcome of AA amyloidosis”. In: Kyle RA, Gertz MA, editions. Amyloid and Amyloidosis 1998. Nashville, TN: Parthenon Publishing (1999): 402-404.
8. Lachmann HJ., et al. “Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy”. British Journal of Haematology1 (2003): 78-84.
9. Comenzo RL., et al. “The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden”. Blood3 (2001): 714-720.
10. Gertz MA., et al. “Amyloidosis”. Best Practice and Research Clinical Haematology4 (2005): 709-727.
11. Benson MD. “Ostertag revisited: the inherited systemic amyloidosis without neuropathy”. Amyloid2 (2005): 75-87.
12. Falk RH. “Diagnosis and management of the cardiac amyloidoses”. Circulation13 (2005): 2047-2060.
13. Merlini G. “CyBorD: stellar response rates in AL amyloidosis”. Blood19 (2012): 4343-4345.
14. Smith TJ., et al. “Clinical significance of histopathologic patterns of cardiac amyloidosis”. Mayo Clinic Proceedings8 (1984): 547-555.
15. Vyndaqel (tafamidis). Ficha técnica (2020).
16. Tree Age pro healthcare (2020).
17. Maurer MS., et al. “ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy”. The New England Journal of Medicine 379 (2018): 1007-1016.